Breakthrough Device designation in 2021, a nod to the transformative nature of its cancer diagnostic tests. Further establishing its credibility, Isabl was granted a direct-to-phase-2 SBIR $2M grant from the NCI to advance Isabl GxT, a specialized test targeting pediatric and rare solid cancers. Under the leadership of founders Dr. Elli Papaemmanuil, Dr. Andrew Kung, and Juan Medina, Isabl's team combines deep expertise in precision medicine, computational biology, and software engineering with a strong track record in biomarker discovery and clinical decision support.